<DOC>
	<DOCNO>NCT02236195</DOCNO>
	<brief_summary>Mocetinostat orally administer histone deacetylase ( HDAC ) inhibitor . This study Phase 2 trial evaluate efficacy mocetinostat patient advance urothelial carcinoma specific change tumor gene . Patients must previously receive treatment chemotherapy include `` platinum-containing agent '' cisplatin . The study enroll stage , 15 patient first stage . More patient add study enough patient beneficial response observe . Mocetinostat administer use oral capsule three time week ( eg , Monday , Wednesday Friday ) . The study design evaluate whether number patient respond treatment substantially high would expect available treatment .</brief_summary>
	<brief_title>Study Mocetinostat Patients With Urothelial Carcinoma Having Inactivating Alterations Specific Genes</brief_title>
	<detailed_description>To eligible study , patient tumor test must demonstrate genetic alteration result loss function Histone Acetyltransferase ( HAT ) family gene , CREBBP and/or EP300 , include gene deletion select inactivate mutation . If test already perform , study provide test .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Diagnosis urothelial carcinoma Metastatic locally advance disease Prior chemotherapy include platinum agent Test result show genetic change tumor gene CREBBP and/or EP300 At least one tumor measure Uncontrolled tumor brain Impaired heart function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Urothelial</keyword>
	<keyword>Bladder</keyword>
	<keyword>HDAC</keyword>
	<keyword>MGCD0103</keyword>
	<keyword>Mocetinostat</keyword>
	<keyword>CREBBP</keyword>
	<keyword>EP300</keyword>
	<keyword>Mirati</keyword>
	<keyword>MethylGene</keyword>
</DOC>